retatrutide phase 2 results obesity nejm 2023 Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks This data from Phase 3

Retatrutide Complete Hub Everything about the triple agonist in one place.

A 180-pound person would lose roughly 40 pounds

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

We monitor the published safety data as each trial phase reports

Understanding the regulatory landscape helps contextualize why products like CrazyLeaf exist in a legal grey zone

This three-pronged approach is what separates it from every other compound on the market or in development